58202-84-9

Basic information

• Product Name: N-(3-CYANOPHENYL)ACETAMIDE
• Synonyms: N-(3-CYANOPHENYL)ACETAMIDE;N-(3-cyanophenyl)acetamide(SALTDATA: FREE);3'-Cyanoacetanilide;N-(3-Cyanophenyl)acetamide, 3-(Acetylamino)benzonitrile
• CAS NO: 58202-84-9
• Molecular Formula: C₉H₈N₂O
• Molecular Weight: 160.17
• Mol File: 58202-84-9.mol
• Article Data: 11

Chemical Properties

• Melting Point: 130 °C
• Boiling Point: 364.3°C at 760 mmHg
• Flash Point: 174.1°C
• Appearance: /
• Density: 1.16g/cm³
• Vapor Pressure: 1.7E-05mmHg at 25°C
• Refractive Index: 1.557
• PKA: 14.34±0.70(Predicted)
• CAS DataBase Reference: N-(3-CYANOPHENYL)ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-CYANOPHENYL)ACETAMIDE(58202-84-9)
• EPA Substance Registry System: N-(3-CYANOPHENYL)ACETAMIDE(58202-84-9)

Safety Data

• Hazardous Substances Data: 58202-84-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H8N2O/c1-7(12)11-9-4-2-3-8(5-9)6-10/h2-5H,1H3,(H,11,12)

Upstream product

• 108-24-7 acetic anhydride 
• 2237-30-1 m-cyanoaniline 
• 99-09-2 3-nitro-aniline 
• 619-24-9 3-nitrobenzonitrile 
• 100-47-0 benzonitrile 
• 75-36-5 acetyl chloride 
• 102-28-3 m-acetamide aniline 
• 91731-84-9 C₁₆H₁₁N₅O 
• 128915-23-1 N-(3-Cyano-phenyl)-N'-(4-nitro-phenyl)-acetamidine 
• 507-09-5 tiolacetic acid 
• 144-55-8 sodium hydrogencarbonate 

Downstream Products

• 1581755-39-6 (R)-N-(3-acetamidobenzyl)-1-(1-(naphthalen-1-yl)ethyl)-piperidine-4-carboxamide 
• 96783-68-5 N-(3-(aminomethyl)phenyl)acetamide 

Relevant articles and documents

Design and synthesis of 3,5-substituted 1,2,4-oxadiazoles as catalytic inhibitors of human DNA topoisomerase IIα

Cancer constitutes a group of diseases linked to abnormal cell growth that can potentially spread to other parts of the body and is one of the most common causes of death. The molecular motors - DNA topoisomerases - that enable topological changes of the DNA molecule are one of the most established targets of cancer therapies. Due to known limitations of established topo II poisons such as cardiotoxicity, induction of secondary malignancies and recognized cancer cell resistance, an emerging group of catalytic topo II inhibitors attempts to circumvent these challenges. Currently, this approach comprises several subgroups of mechanistically diverse inhibitors, one of which are compounds that act by binding to their ATPase domain. In this study we have designed, synthesized and characterized a new series of 3,5-substituted 1,2,4-oxadiazoles that act as catalytic inhibitors of human topo IIα. The introduction of the substituted rigid substitutions on the oxadiazole backbone was intended to enhance the interactions with the ATP binding site. In the inhibition assays selected compounds revealed a new class of catalytic inhibitors targeting this molecular motor and showed binding to the isolated topo IIα ATPase domain. The predicted inhibitor binding geometries were evaluated in molecular dynamics simulations and subsequently dynophore models were derived, which provided a deeper insight into molecular recognition with its macromolecular target. Selected compounds also displayed in vitro cytotoxicity on the investigated MCF-7 cancer cell line and did not induce double-strand breaks (DSB), thus displaying a mechanism of action diverse from the topo II poisons also on the cellular level. The substituted oxadiazoles thus comprise a chemical class of interesting compounds that are synthetically fully amenable for further optimization to anticancer drugs.

Solvatochromic probes for detecting hydrogen-bond-donating solvents

Hydrogen bonding heavily influences conformations, rate of reactions, and chemical equilibria. The development of a method to monitor hydrogen bonding interactions independent of polarity is challenging as both are linked. We have developed two solvatochr

APO AI EXPRESSION ACCELERATING AGENT

Pharmaceutical compositions for enhancing the expression of apoAI are provided.Pharmaceutical compositions for enhancing the expression of apoAI which comprises a compound of formula (I): in which Y1 is O, S or NR1; Y2, Y